Organon’s stock slides after announcing deal with Forendo Pharma

Shares of Organon & Co.
OGN,
-6.09%
were down 6.7% in trading on Thursday after the company said it plans to acquire Forendo Pharma, a privately held company developing an endometriosis therapy. As part of the agreement, Organon will pay $75 million…

Click here to view the original article.